Ann: Opthea announces A$80m Capital raise, page-49

Primaus72, on a successful P3 result it's hard to imagine this not gapping up to an A$2-4b market cap, so as much as the criticism may be warranted, the new shares don't really change the investment thesis. The trial has taken a lot longer than anticipated / hoped. This is likely due to competitor trials making recruitment harder or competitors actively trying to delay progress via lobbying, PR or other dirty tricks. When huge money is at stake it's never going to be easy to get over the P3 line.

I've therefore no interest in buying until both trials are fully recruited, so likely 6-9 months time. At that point I suspect the worm will start to turn, right now there is still far too much time for the hedgies to squeeze the last drops out of retail.